Recommendation ID
TA340/1
Question

NICE considered that there is an important need for head-to-head comparisons between biological treatments for psoriatic arthritis, particularly in people for whom treatment with tumour necrosis factor (TNF) alpha inhibitors has been unsuccessful.

Any explanatory notes
(if applicable)

None.


Source guidance details

Comes from guidance
Ustekinumab for treating active psoriatic arthritis
Number
TA340
Date issued
June 2015

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No